Methadone Hydrochloride Injection is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.
From the U.S. FDA-approved label for Methadone. Full label: DailyMed.
Methadone Hydrochloride Injection is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.
From the U.S. FDA-approved label for Methadone. Full label: DailyMed.
Important General Information Consider the following important factors that differentiate methadone from other opioids: The peak respiratory depressant effect of methadone occurs later and persists longer than its peak pharmacologic effect., A high degree of opioid tolerance does not eliminate the possibility of methadone overdose, iatrogenic or otherwise.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
Methadone Hydrochloride Injection is contraindicated in patients with: Significant respiratory depression, Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment, Known or suspected gastrointestinal obstruction, including paralytic ileus, Hypersensitivity to methadone hydrochloride (e.g. anaphylaxis) or any other ingredient in Methadone Hydrochloride Injection.
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
Addiction, Abuse and Misuse Methadone Hydrochloride Injection contains methadone, a Schedule II controlled substance. As an opioid, Methadone Hydrochloride Injection exposes users to the risks of addiction, abuse, and misuse. Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed Methadone Hydrochloride Injection. Addiction can occur at recommended doses and if the drug is misused or abused. The risk of opioid-related overdose or overdose-related death is increased with higher opioid doses, and this risk persists over the course of therapy.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
The following serious adverse reactions are described, or described in greater detail, in other sections: Addiction, Abuse, and Misuse (see WARNINGS ), Life Threatening Respiratory Depression (see WARNINGS ), QT Prolongation (see WARNINGS ), Neonatal Opioid Withdrawal Syndrome (see WARNINGS ), Interactions with CNS Depressants (see WARNINGS ), Serotonin Syndrome (see WARNINGS ), Adrenal Insufficiency (see WARNINGS ), Severe…
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
Store at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Protect from light.
Storage information from the U.S. FDA-approved label.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
